Text Size: A | A | A

Features

A More Strategic Approach to Medical Meetings

Why med/pharma companies are ramping up SMM

by Michael J. ShapiroFebruary 1, 2013

illustration2

Meetings Under a Microscope

Betty McNulty
The interest in meetings spend at med/pharma firms is increasingly becoming more pronounced throughout each company, says Betty McNulty, general manager, enterprise, of the ACTIVE Network Business Solutions Group. "Procurement has always had a seat at the table with respect to our SMM solutions," she notes. "But especially in the Life Sciences sector, there is a greater participation of various areas in the organization." From procurement to sales and marketing to finance and R&D, it's crucial that each has detailed data, especially with respect to interactions with health-care professionals. "It really spans across all of the different operating areas that have a vested interest in how these meetings and events occur," she explains, "especially over the last year or two." -- M.J.S.

A fresh imperative to keep records
The impending reporting requirements are acting as a catalyst for SMMP development in health-care fields, explains Debi Scholar, president of the Scholar Consulting Group in Scotch Plains, N.J. That's notable, says the strategic meetings management expert, because SMM currently is taking a backseat to tactical meeting planning in many other industries. "Meetings are picking up and hotels are filling up," Scholar points out, "but resources are rarely being added to meetings programs right now. Planners are being asked to do more with less, and it's becoming hard for people at many companies to find time and resources for strategy planning. But the pharma industry is the main exception to this trend; because of the Sunshine Act, they just can't afford to put SMM on the back burner."

That's despite the fact that medical-meetings professionals still are awaiting the final requirements on just what must be reported and how. The Centers of Medicare & Medicaid Services, the government entity charged with stipulating the precise requirements, could issue that ruling by the end of this month. Companies originally were supposed to file their first payments report by March 31 of this year; while that will almost certainly be delayed, the companies must nevertheless have been collecting, for the past year, all potentially relevant data to ensure they are ready to report when charged to do so.

In the meantime, "Most companies have the bones of an SMMP in place, or at least the inklings of it," Steve O'Malley says of the health-care firms he works with at Maxvantage. The biggest pharmaceutical clients -- ones his company has been serving for many years -- have some of the most mature and robust SMMPs in any industry, says O'Malley. The challenge now, he notes, is processing all of the payment data they're required to collect: "We've got this whole new stream of data. How do we put it all together in a way that makes sense? How do we get the best holistic view so that it's actionable and useful to each company, in addition to being reportable?"

The need to take a basic SMM program to the next level is something O'Malley says is coming up in nearly every discussion with prospective clients these days. "Many really don't have a grip on the right kind of data that they need to fulfill reporting requirements," he says. "In many cases, companies purchase technology they think will give them all the information they need. But buying the technology alone is not an SMMP. You also have to have the people and the processes in place to get what you need from that technology."

Representatives from Active Network and Cvent, two major providers of such technology, say they're seeing more clients looking beyond piecemeal technology tools. "We're dealing a lot with companies that are either implementing SMMPs or have an SMM focus," says Lisa Palmeri, a former pharma planner who is now director of professional services at Cvent. "They're looking for an end-to-end solution to help them automate their meeting policies, meeting processes and standard operating procedures."

However, unlike the largest firms, many small to midsize pharma and medical-device companies have only recently realized the importance of SMM, notes Debi Scholar. "Many have not taken it seriously," she says, "and because the Sunshine Act requirements were delayed again, some have been able to skirt the implementation of technology and SMM plans a little longer."

Such lack of concern worries James Vachon, associate director of corporate meetings and conventions for Millennium Pharmaceuticals, whose events, meetings and conventions group serves the 1,100-employee biopharmaceutical company in Cambridge, Mass. While the meetings program at Millennium enjoys the full support of its parent company, the Japanese pharma giant Takeda, Vachon has been disheartened to see far less support at many other small pharmas -- and, in some cases, the dissolution of meetings groups altogether.

"When you have organizations that don't understand the value of groups like ours," notes Vachon, "and they don't see the benefits of an SMMP, you have to ask the question: How are you managing the liability that comes with all of these regulatory guidelines that you have to follow and the compliance issues that we have to be conscientious of? A company can be opening itself up to an enormous amount of liability if it's not working with the right people. When you don't have a group within the organization to define who those right partners are, it could be, especially in this day and age, really detrimental."


<< Prev | 1 | 2 | 3 | Next >>
This page is protected by Copyright laws. Do Not Copy
Text Size: A | A | A
blog comments powered by Disqus

Latest Top News:
Career Development
Corporate Topics
Features
Gold Awards Elite Winners Planner Basics